Drug Profile
Cabotegravir - ViiV Healthcare
Alternative Names: 1265744; 744 LA Injection; APRETUDE; Apretude; CAB LA - ViiV Healthcare; Cabotegravir long acting; Cabotegravir sodium; GSK-1265744; GSK-1265744A; GSK-1265744B; GSK-744; GSK-744-LA; GSK1265744 LAP; S-265744; S-265744B; S/GSK-1265744; S/GSK1265744 LAPLatest Information Update: 07 Mar 2024
Price :
$50
*
At a glance
- Originator Shionogi - GlaxoSmithKline (JV)
- Developer Gilead Sciences; National Institute of Allergy and Infectious Diseases; ViiV Healthcare
- Class Amides; Antiretrovirals; Fluorobenzenes; Oxazoles; Pyrazines; Pyridones; Small molecules
- Mechanism of Action HIV integrase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed HIV infections
- Registered HIV-1 infections
Most Recent Events
- 04 Mar 2024 Updated pharmacokinetic data from a phase I trial in HIV infections presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2024)
- 03 Mar 2024 Interim adverse events and efficacy data from a phase-II trial in HIV infections presented at the Conference on Retroviruses and Opportunistic Infections 2024 (CROI-2024)
- 03 Mar 2024 Updated adverse event and pharmacokinetic data from a phase I trial in HIV infections presented at the 31st Conference on Retroviruses and Opportunistic Infections 2024 (CROI-2024)